Literature DB >> 17591618

Site-specific N-glycan characterization of human complement factor H.

François Fenaille1, Maxime Le Mignon, Catherine Groseil, Christine Ramon, Sandrine Riandé, Laurent Siret, Nicolas Bihoreau.   

Abstract

Human complement factor H (CFH) is a plasma glycoprotein involved in the regulation of the alternative pathway of the complement system. A deficiency in CFH is a cause of severe pathologies like atypical haemolytic uraemic syndrome (aHUS). CFH is a 155-kDa glycoprotein containing nine potential N-glycosylation sites. In the current study, we present a quantitative glycosylation analysis of CFH using capillary electrophoresis and a complete site-specific N-glycan characterization using matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) and liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESIMS/MS). A 17.9-kDa mass decrease, observed after glycosidase treatment, indicated that N-glycosylation is the major post-translational modification of CFH. This mass difference is consistent with CFH glycosylation by diantennary disialylated glycans of 2204 Da on eight sites. CFH was not sensitive to endoglycosidase H (Endo H) deglycosylation, indicating the absence of hybrid and oligomannose structures. Quantitative analysis showed that CFH is mainly glycosylated by complex, diantennary disialylated, non-fucosylated glycans. Disialylated fucosylated and monosialylated non-fucosylated oligosaccharides were also identified. MS analysis allowed complete characterization of the protein backbone, verification of the glycosylation sites and site-specific N-glycan identification. The absence of glycosylation at Asn199 of the NGSP sequence of CFH is shown. Asn511, Asn700, Asn784, Asn804, Asn864, Asn893, Asn1011 and Asn1077 are glycosylated essentially by diantennary disialylated structures with a relative distribution varying between 45% for Asn804 and 75% for Asn864. Diantennary monosialylated glycans and triantennary trisialylated fucosylated and non-fucosylated structures have also been identified. Interestingly, the sialylation level along with the amount of triantennary structures decreases from the N- to the C-terminal side of the protein.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591618     DOI: 10.1093/glycob/cwm060

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  25 in total

1.  Analysis of site-specific glycosylation of renal and hepatic γ-glutamyl transpeptidase from normal human tissue.

Authors:  Matthew B West; Zaneer M Segu; Christa L Feasley; Pilsoo Kang; Iveta Klouckova; Chenglong Li; Milos V Novotny; Christopher M West; Yehia Mechref; Marie H Hanigan
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

2.  Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.

Authors:  Stefan Michelfelder; Juliana Parsons; Lennard L Bohlender; Sebastian N W Hoernstein; Holger Niederkrüger; Andreas Busch; Nicola Krieghoff; Jonas Koch; Benjamin Fode; Andreas Schaaf; Thomas Frischmuth; Martin Pohl; Peter F Zipfel; Ralf Reski; Eva L Decker; Karsten Häffner
Journal:  J Am Soc Nephrol       Date:  2016-12-08       Impact factor: 10.121

3.  Three surface exoglycosidases from Streptococcus pneumoniae, NanA, BgaA, and StrH, promote resistance to opsonophagocytic killing by human neutrophils.

Authors:  Ankur B Dalia; Alistair J Standish; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2010-02-16       Impact factor: 3.441

4.  Zebrafish complement factor H and its related genes: identification, evolution, and expression.

Authors:  Guanni Sun; Hongyan Li; Yuan Wang; Baohong Zhang; Shicui Zhang
Journal:  Funct Integr Genomics       Date:  2010-07-29       Impact factor: 3.410

5.  The solution structure of the complement deregulator FHR5 reveals a compact dimer and provides new insights into CFHR5 nephropathy.

Authors:  Nilufar Kadkhodayi-Kholghi; Jayesh S Bhatt; Jayesh Gor; Lindsay C McDermott; Daniel P Gale; Stephen J Perkins
Journal:  J Biol Chem       Date:  2020-09-14       Impact factor: 5.157

6.  Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations.

Authors:  Azubuike I Okemefuna; Ruodan Nan; Ami Miller; Jayesh Gor; Stephen J Perkins
Journal:  J Biol Chem       Date:  2009-10-22       Impact factor: 5.157

7.  Mass spectrometric characterization of N- and O-glycans of plasma-derived coagulation factor VII.

Authors:  François Fenaille; Catherine Groseil; Christine Ramon; Sandrine Riandé; Laurent Siret; Sami Chtourou; Nicolas Bihoreau
Journal:  Glycoconj J       Date:  2008-07-20       Impact factor: 2.916

8.  Rapid and sensitive method for detection of Y402, H402, I62, and V62 variants of complement factor H in human plasma samples using mass spectrometry.

Authors:  Una Kelly; Catherine Bowes Rickman; Eric A Postel; Michael A Hauser; Gregory S Hageman; Vadim Y Arshavsky; Nikolai P Skiba
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-11-21       Impact factor: 4.799

9.  Production of biologically active complement factor H in therapeutically useful quantities.

Authors:  Christoph Q Schmidt; Fern C Slingsby; Anna Richards; Paul N Barlow
Journal:  Protein Expr Purif       Date:  2010-12-10       Impact factor: 1.650

10.  An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.

Authors:  Yi Yang; Harriet Denton; Owen R Davies; Kate Smith-Jackson; Heather Kerr; Andrew P Herbert; Paul N Barlow; Matthew C Pickering; Kevin J Marchbank
Journal:  J Am Soc Nephrol       Date:  2018-03-27       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.